ISS Urges Shareholders to Remove
Falcone From HC2 Board
The proxy adviser wants investors to
support three of six dissident candidates to the miniconglomerate’s
six-person board and to remove the company’s chief executive, Philip
Falcone, from its oversight panel.
By Ronald
Orol
Updated on April 24, 2020, 12:16 PM ET
Philip Falcone |
Institutional Shareholder Services Inc. has urged
shareholders of HC2
Holdings Inc. (HCHC) to vote in favor of removing of Philip
Falcone and two other directors from miniconglomerate's board.
The proxy adviser issued a report, obtained by The Deal on Friday,
April 24, that recommended investors back three of six dissident
director candidates nominated by ex-Third
Point LLC analyst Michael Gorzynski for HC2's six-person
board.
“The dissident makes a strong case that significant board change is
necessary to address the company's prolonged underperformance, need to
reduce and potentially refinance debt, excessive executive
compensation and a lack of credibility surrounding CEO Falcone,” ISS said
in its report.
Gorzynski, manager of MG Capital Management LP, is seeking to install
candidates through a written consent solicitation process set to
conclude on May 7. Consents for director candidates are due to be
tallied and delivered to the company's proxy solicitor by May 12.
The insurgent manager wants to oust Falcone from his role of CEO and
push the company to focus on its core assets, including DBM
Global and Continental General, while divesting other units.
In addition, Gorzynski wants to become interim CEO in Falcone’s stead.
HC2 has business operations in construction, marine services,
insurance and other sectors.
ISS said MG Capital has presented a "compelling" case but added that
it is not yet clear whether its divestiture plan is “the best way
forward.” In addition, ISS noted shareholders may have some
reservations regarding Gorzynski’s ability as interim CEO “given his
lack of experience as a public company executive or director.”
The adviser is recommending that shareholders don’t vote to install
Gorzynski, one of MG Capital’s candidates, as a director.
An MG Capital presentation defended Gorzynski's experience, noting he
has participated in "dozens of insurance and debt-related
restructurings" and that its candidates have committed to cutting
director fees by 50% and providing the activist investor $1 for his
potential service as interim CEO.
ISS was critical of Falcone. It said it may be difficult to convince
the market of management’s ability to generate shareholder value with
“Falcone at the helm.” The proxy adviser pointed to “refinancing
missteps, questionable accounting decisions and Falcone's prior
litigious history” as reasons to remove him from the board.
Seeking to appease disgruntled investors, HC2 announced Tuesday it was
installing a new director, Lancer Capital LLC’s Avram Glazer, as board
chairman. HC2’s interim chairman, Warren Gfeller, has described Glazer
as an “independent and high-quality nominee.” However, Glazer has connections to
Gfeller, Falcone and HC2 that suggest he isn’t very independent.
Even so, ISS said Glazer’s appointment was a “step in the right
direction” and that he is a “significant shareholder with prior public
board experience.” Glazer’s Lancer Capital owns 5.3%.
In a statement, HC2 said it strongly disagrees with ISS’s
recommendation but it was pleased with the adviser’s support of three
incumbent directors and the potential appointment of Glazer as board
chairman.
In addition, another activist, Julian Singer, a 6.4% holder, reported
support for Glazer’s nomination on Tuesday. Singer said April 7 that
he didn't support MG Capital’s campaign.
In a related matter, a Delaware judge tentatively scheduled an
expedited preliminary injunction hearing for May 1 regarding an
investor’s lawsuit targeting a “poison put” defense the company set up
in response to the Gorzynski contest.
At issue in the lawsuit is whether a Gorzynski board control win would
trigger a provision of HC2’s bylaws requiring that the company
repurchase up to $27 million in preferred share securities. HC2 has
said it may not have “sufficient proceeds” or the “financing
available” to fund such a preferred share securities purchase.
Critics of the provision argue the company is seeking to discourage
investors from supporting the activist slate by suggesting their
installation on the board would trigger the payment.
HC2 has given mixed messages about whether the poison put would be
triggered in the event the dissidents were elected.
In revised disclosures, the company said April 17 it believed the
election of the dissidents will “not trigger” a requirement for the
company to make an offer to holders of preferred stock to redeem their
stakes. However, the company added that preferred stockholders may
take “a different view” if the dissident directors are elected and may
“allege that the company is required to make an offer to redeem” their
positions.
The Delaware lawsuit is ongoing.
|